Resolve Nanotherapeutics is developing a first-in-class RNA therapeutic delivered via lipid nanoparticles to treat severe acute bacterial infections like pneumonia and peritonitis. The host-directed therapy amplifies the body's natural toxin-clearance pathway, neutralizing bacteria regardless of antibiotic resistance without driving new resistance. The platform has demonstrated reduced mortality in resistant pneumonia models and targets validated human genetic pathways.
Funding
Funding not disclosed
Founders
Product
Problem
Acute bacterial infections such as pneumonia and peritonitis are leading global killers, with mortality rates reaching 15-45% within the first month and survivors often facing re-admission, organ damage, and cognitive decline. The rise of antibiotic resistance threatens to render current treatments ineffective within 15-20 years, while the drug development pipeline for new antibiotics remains insufficient to keep pace with bacterial evolution.
Solution
Resolve Nanotherapeutics is developing a host-directed RNA therapeutic delivered via lipid nanoparticles (LNPs) that amplifies the body's innate ability to clear bacterial toxins. Rather than attacking microbes directly, this approach reduces damaging inflammation and prevents organ damage, working across all bacterial species regardless of resistance profile. The therapy targets genetically validated pathways—human studies show that individuals with genetic mutations activating this toxin-clearance pathway survive sepsis up to 25% more often. A single intravenous dose rapidly upregulates the target pathway, and preclinical studies have demonstrated reduced mortality in resistant pneumonia models.
Target Audience
Primary customers are hospitals and intensive care units treating patients with severe acute bacterial infections, including pneumonia, peritonitis, and febrile neutropenia, as well as healthcare systems seeking resistance-proof therapeutic options beyond conventional antibiotics.
Features
- LNP-RNA delivery platform that switches validated gene targets on or off within hours, enabling rapid therapeutic response
- Host-focused mechanism with no direct pressure on pathogens, eliminating a clear pathway for bacterial resistance development
- Broad-spectrum activity against all bacterial species, including mixed ICU infections and antibiotic-resistant strains
- Genetic validation from human data showing up to 25% improved sepsis survival in individuals with activated toxin-clearance pathways
- Clinically proven LNP technology with established scalability and manufacturing feasibility
- Single-dose intravenous administration designed for acute care settings